Literature DB >> 32277046

Identification of known and unknown genes associated with mitral valve prolapse using an exome slice methodology.

Aniek L van Wijngaarden1, Yasmine L Hiemstra1, Tamara T Koopmann2, Claudia A L Ruivenkamp2, Emmelien Aten2, Martin J Schalij1, Jeroen J Bax1, Victoria Delgado1, Daniela Q C M Barge-Schaapveld2, Nina Ajmone Marsan3.   

Abstract

PURPOSE: Although a familial distribution has been documented, the genetic aetiology of mitral valve prolapse (MVP) is largely unknown, with only four genes identified so far: FLNA, DCHS1, DZIP1 and PLD1. The aim of this study was to evaluate the genetic yield in known causative genes and to identify possible novel genes associated with MVP using a heart gene panel based on exome sequencing.
METHODS: Patients with MVP were referred for genetic counselling when a positive family history for MVP was reported and/or Barlow's disease was diagnosed. In total, 101 probands were included to identify potentially pathogenic variants in a set of 522 genes associated with cardiac development and/or diseases.
RESULTS: 97 (96%) probands were classified as Barlow's disease and 4 (4%) as fibroelastic deficiency. Only one patient (1%) had a likely pathogenic variant in the known causative genes (DCHS1). However, an interesting finding was that 10 probands (11%) had a variant that was classified as likely pathogenic in six different, mostly cardiomyopathy genes: DSP (1×), HCN4 (1×), MYH6 (1×), TMEM67 (1×), TRPS1 (1×) and TTN (5×).
CONCLUSION: Exome slice sequencing analysis performed in MVP probands reveals a low genetic yield in known causative genes but may expand the cardiac phenotype of other genes. This study suggests for the first time that also genes related to cardiomyopathy may be associated with MVP. This highlights the importance to screen these patients and their family for the presence of arrhythmias and of 'disproportionate' LV remodelling as compared with the severity of mitral regurgitation, unravelling a possible coexistent cardiomyopathy. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  clinical genetics; valvar diseases

Mesh:

Substances:

Year:  2020        PMID: 32277046     DOI: 10.1136/jmedgenet-2019-106715

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

1.  Malignant Mitral Valve Prolapse: Risk and Prevention of Sudden Cardiac Death.

Authors:  Yasufumi Nagata; Philippe B Bertrand; Robert A Levine
Journal:  Curr Treat Options Cardiovasc Med       Date:  2022-03-22

2.  Significance of α-Myosin Heavy Chain (MYH6) Variants in Hypoplastic Left Heart Syndrome and Related Cardiovascular Diseases.

Authors:  Melissa Anfinson; Robert H Fitts; John W Lough; Jeanne M James; Pippa M Simpson; Stephanie S Handler; Michael E Mitchell; Aoy Tomita-Mitchell
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-03

Review 3.  Left Ventricular Remodeling in Non-syndromic Mitral Valve Prolapse: Volume Overload or Concomitant Cardiomyopathy?

Authors:  Lobke L Pype; Philippe B Bertrand; Bernard P Paelinck; Hein Heidbuchel; Emeline M Van Craenenbroeck; Caroline M Van De Heyning
Journal:  Front Cardiovasc Med       Date:  2022-04-12

4.  Malignant Arrhythmic Mitral Valve Prolapse: A Continuum of Clinical Challenges from Diagnosis to Risk Stratification and Patient Management.

Authors:  Idit Yedidya; Aniek L van Wijngaarden; Nina Ajmone Marsan
Journal:  J Cardiovasc Dev Dis       Date:  2020-12-29

5.  Commentary: The Barlow valve: Understanding disease and symmetry.

Authors:  Carlos A Mestres; Miguel A Piñón; Eduard Quintana
Journal:  JTCVS Tech       Date:  2021-10-09

Review 6.  Arrhythmic Mitral Valve Prolapse and Mitral Annular Disjunction: Clinical Features, Pathophysiology, Risk Stratification, and Management.

Authors:  Apurba K Chakrabarti; Frank Bogun; Jackson J Liang
Journal:  J Cardiovasc Dev Dis       Date:  2022-02-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.